Daily GLP-1 receptor agonist pill leads to ‘significant’ weight loss

Daily treatment with oral glucagon-like peptide-1 (GLP-1) receptor agonist orforglipron (Emgality; Eli Lilly) results in substantial weight loss in people living with obesity who did not have type 2 diabetes mellitus, according to results from a phase III, multinational, randomised double-blind trial of the once-daily pill. The drug is currently being appraised by the National […]

Publication Details

Journal: Pharmaceutical journal/The pharmaceutical journal
Published: 2025-01-01
DOI: https://doi.org/10.1211/pj.2025.1.374505
Primary Topic: Diabetes Treatment and Management
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Daily GLP-1 receptor agonist pill leads to ‘significant’ weight loss

Jan 1, 2025

Pharmaceutical journal/The pharmaceutical journal

Diabetes Treatment and Management

article

Daily GLP-1 receptor agonist pill leads to ‘significant’ weight loss

January 1, 2025article en

Abstract

Pharmaceutical journal/The pharmaceutical journal

Openalex Percentile: Top 65%

Diabetes Treatment and Management

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Daily GLP-1 receptor agonist pill leads to ‘significant’ weight loss · Pharmaceutical journal/The pharmaceutical journal (2025) | TGRS Research Map | TGRS